Related Experiment Video

Updated: Jun 19, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.0K

Assessing monoclonal antibodies for respiratory virus infections

Nicholas J White1, William H K Schilling1, Podjanee Jittamala2

  • 1Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Lancet (London, England)
|August 9, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.1K
Assessing Respiratory Immune Responses to Haemophilus Influenzae
06:32

Assessing Respiratory Immune Responses to Haemophilus Influenzae

Published on: June 29, 2021

2.3K

Related Experiment Videos

Last Updated: Jun 19, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.0K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.1K
Assessing Respiratory Immune Responses to Haemophilus Influenzae
06:32

Assessing Respiratory Immune Responses to Haemophilus Influenzae

Published on: June 29, 2021

2.3K

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

Articles linked to this work by shared authors, journal, and citation graph.

Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial.

The Lancet. Infectious diseases·2026

Transmission of rifampicin-resistant tuberculosis in Ho Chi Minh City, Viet Nam: a prospective genomic epidemiology study.

The Lancet regional health. Western Pacific·2026

Effect of higher dose primaquine for the radical cure of Plasmodium vivax malaria in Indonesia: a systematic review and individual patient data meta-analysis.

The Lancet regional health. Western Pacific·2026

A systematic mapping review of therapeutic clinical trials in dengue.

PLoS neglected tropical diseases·2026

MeCP2 requires interactions with nucleosome linker DNA to read chromatin DNA methylation.

Nature communications·2026

Trypanosome histone variants H3.V and H4.V promote nucleosome plasticity in repressed chromatin.

Structure (London, England : 1993)·2026

Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark.

Lancet (London, England)·2026

Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial.

Lancet (London, England)·2026

Cardiovascular disease in pregnancy: physiology, global burden, risk stratification, and opportunities in care.

Lancet (London, England)·2026

Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II): a prospective, multicentre, observational cohort study.

Lancet (London, England)·2026

Adverse pregnancy outcomes and long-term cardiovascular disease risk.

Lancet (London, England)·2026

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.

Lancet (London, England)·2026

Species-specific iNOS expression distinguishes epithelial and myeloid IFNγ responses in tuberculosis.

American journal of respiratory cell and molecular biology·2026

Evaluating an anti-idiotype derived germline-targeting immunogen designed to elicit VRC01-class precursors in human antibody transgenic mice.

mSphere·2026

Unraveling the drug resistance web in IBD: The gut microbiota-immunity-epigenetics axis.

Gut microbes·2026

Immunometabolic Control of Neutrophil Plasticity in Tuberculosis.

Cell biology international·2026

Probable Coxsackievirus Infection in an Immunocompetent Adult With Genital and Oral Ulcerations Mimicking Herpes Simplex Virus Infection and Behçet's Disease.

Cureus·2026

Intestinal stem cells as innate immune sentinels: coupling environmental sensing to epithelial adaptation.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us